TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39094432

Group type: EXPERIMENTAL
Intervention: CER-0001 (up to 30 g twice a day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 39094560

Group type: EXPERIMENTAL
Intervention: NACRT and PD-1 antibody sintilimab
Number of subjects: 134

Group type: COMPARATOR
Intervention: NACRT
Number of subjects: 134
Study: 39094630

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 1468
Study: 39094677

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 39094733

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS) ≥ median
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: Ratio of the pulmonary artery to aorta diameters (PA:A ratio) ≥ 1
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: CACS/CVD in NEPD vs EPD
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: PA:A ratio/COPD exacerbation in NEPD vs EPD
Number of subjects: 2791
Study: 39094734

Group type: EXPERIMENTAL
Intervention: SWI-/SNF-deficient undifferentiated carcinomas
Number of subjects: 59
Study: 39094743

Group type: EXPERIMENTAL
Intervention: PegIFN-α-2a treatment for 48 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: NUC cessation
Number of subjects: 180
Study: 39095086

Group type: EXPERIMENTAL
Intervention: Balloon-assisted coiling (BAC)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Stent-assisted coiling (SAC)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Flow diversion (FD)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Coiling alone
Number of subjects: 233
Study: 39095206

Group type: EXPERIMENTAL
Intervention: Vascular senescence group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rat models with vascular senescence
Number of subjects: 0
Study: 39095502

Group type: EXPERIMENTAL
Intervention: High baseline NPCs ratio (≥5%)
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: High residual NPCs ratio at diagnosis or relapse
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: High absolute percentages of NPCs at undetectable MRD
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Grouping based on NPCs ratio at MRD-positive phases (<50%, 50-90%, ≥90%)
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Dynamic MRD model based on NPCs ratio trend
Number of subjects: 1363
Study: 39095524

Group type: EXPERIMENTAL
Intervention: Room Air (RA) challenge
Number of subjects: 1022
Study: 39095560

Group type: EXPERIMENTAL
Intervention: Obsidian RFT
Number of subjects: 15
Study: 39095571

Group type: EXPERIMENTAL
Intervention: Behavioral Health (BH) care management including cognitive behavioral therapy, medication adjustments, and case management
Number of subjects: 632

Group type: COMPARATOR
Intervention: Electronic Medical Record Clinical Decision Support (EMR-CDS)
Number of subjects: 632
Study: 39095597

Group type: EXPERIMENTAL
Intervention: L. major-infected Phlebotomus duboscqi
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Therapeutic biopsy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Follow-up at >12 months
Number of subjects: 14
Study: 39095724

Group type: EXPERIMENTAL
Intervention: Simple resistance training (SRA)
Number of subjects: 17
Study: 39095735

Group type: EXPERIMENTAL
Intervention: 6-month supervised structured exercise intervention emphasizing increasing and varied intensities of aerobic and resistance exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6-month supervised structured exercise intervention
Number of subjects: 12
Study: 39095759

Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography-guided pancreatic arterial infusion (PAI) of GEMOX chemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous chemotherapy (IVC) of GEMOX
Number of subjects: 51
Study: 39095808

Group type: EXPERIMENTAL
Intervention: NT-proBNP quartiles
Number of subjects: 685
Study: 39095818

Group type: EXPERIMENTAL
Intervention: Bone lid technique using a piezoelectric device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional method using rotatory burs
Number of subjects: 24
Study: 39095860

Group type: EXPERIMENTAL
Intervention: Probiotics after GA
Number of subjects: 58

Group type: COMPARATOR
Intervention: No probiotics after GA
Number of subjects: 58
Study: 39095863

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention (completed six sessions)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention (for women with mild anxiety)
Number of subjects: 720
Study: 39095866

Group type: EXPERIMENTAL
Intervention: Caplacizumab (10 mg daily) with therapeutic plasma exchange (TPE) and immunosuppression for 30 days post-TPE
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Caplacizumab with TPE and immunosuppression
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rituximab administered to patients with inhibitor boosting (88.9%) after TPE completion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rituximab administered to patients without inhibitor boosting prior to TPE completion
Number of subjects: 19
Study: 39095876

Group type: EXPERIMENTAL
Intervention: Online membership-based fitness program (8-week duration, includes 16 pre-recorded videos and 9 live exercise classes)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Online membership-based fitness program
Number of subjects: 31
Study: 39095884

Group type: COMPARATOR
Intervention: rs-fMRI activity in resuscitated patients
Number of subjects: 31
Study: 39095919

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1500 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 39095923

Group type: EXPERIMENTAL
Intervention: Stimdia's pdSTIM System (phrenic nerve stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study: 39096236

Group type: EXPERIMENTAL
Intervention: Cognitive reserve
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Affective reserve
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Current lifestyle
Number of subjects: 404

Group type: COMPARATOR
Intervention: Cumulative exposure to age-related stressors and COVID-19 infection
Number of subjects: 404
Study: 39096467

Group type: EXPERIMENTAL
Intervention: Cenobamate (CNB)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Other ASMs (including valproate, lacosamide, levetiracetam, topiramate)
Number of subjects: 231
Study: 39096659

Group type: EXPERIMENTAL
Intervention: ISIS721744 (antisense therapy to block prekallikrein), one subcutaneous dose
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 39096895

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 464
Study: 39096924

Group type: EXPERIMENTAL
Intervention: Molecularly guided therapy (MGT)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Standard platinum-based chemotherapy
Number of subjects: 436
Study: 39096929

Group type: EXPERIMENTAL
Intervention: iscalimab 150 mg
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: iscalimab 300 mg
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: iscalimab 600 mg
Number of subjects: 273

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 273
Study: 39097000

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) program based on cognitive behavioral therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 39097304

Group type: EXPERIMENTAL
Intervention: Minimally invasive lung surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative assessments using Numeric Pain Rating Scale and Visual Analogue Scale score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leicester Cough Questionnaire, Brief Pain Inventory, McGill Pain Questionnaire, EORTC QLQ-C30, HADS
Number of subjects: 0
Study: 39097307

Group type: EXPERIMENTAL
Intervention: Pressure support adjusted according to PMI strategy for 48 hours
Number of subjects: 60
Study: 39097313

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 39097315

Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing programme
Number of subjects: 244

Group type: COMPARATOR
Intervention: Treatment as usual (annual oral health awareness visit)
Number of subjects: 244
Study: 39097328

Group type: EXPERIMENTAL
Intervention: EDACS score ≥16
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TIMI risk score ≥1
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: GRACE score >88
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TIMI score of 0
Number of subjects: 167
Study: 39097413

Group type: EXPERIMENTAL
Intervention: Davoceticept monotherapy (0.001-10 mg/kg, intravenous, Q1W or Q3W)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Davoceticept and pembrolizumab combination (davoceticept 0.1 or 0.3 mg/kg, intravenous, Q1W or Q3W; pembrolizumab 400 mg every 6 weeks)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Davoceticept monotherapy and combination with pembrolizumab
Number of subjects: 87
Study: 39097467

Group type: EXPERIMENTAL
Intervention: Nivolumab-plus-ipilimumab
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1166
Study: 39097500

Group type: EXPERIMENTAL
Intervention: Nivolumab ± ipilimumab second-line immunotherapy
Number of subjects: 66
Study: 39097549

Group type: EXPERIMENTAL
Intervention: GB05 (1.2 million IU)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GB05 (1.8 million IU)
Number of subjects: 35

Group type: COMPARATOR
Intervention: GB05 (0.2 million IU)
Number of subjects: 35

Group type: COMPARATOR
Intervention: GB05 (0.6 million IU)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 39097566

Group type: EXPERIMENTAL
Intervention: Personalized insulin dosing using reinforcement learning for high-fat meals
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Personalized insulin dosing using reinforcement learning for meals followed by aerobic exercises
Number of subjects: 15
Study: 39097695

Group type: EXPERIMENTAL
Intervention: Locomotor training in a movement amplification environment (experimental group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Locomotor training in a traditional treadmill environment (control group)
Number of subjects: 36
Study: 39097718

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during port and vein punctures
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 57
Study: 39097733

Group type: EXPERIMENTAL
Intervention: FamPALcare intervention (five telephone coaching sessions on HF home, palliative, and end-of-life care)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: FamPALcare intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 39097739

Group type: EXPERIMENTAL
Intervention: Electrodermal activity (EDA) and electrocardiogram (ECG) signals
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multivariable regression analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clustering analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Subjective pain perception
Number of subjects: 64
Study: 39097916

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoimmunotherapy (nCIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: chemotherapy (nCT)
Number of subjects: 81
Study: 39097924

Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg three times daily (TET-T)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Tetracycline 500 mg four times daily (TET-F)
Number of subjects: 406
Study: 39097970

Group type: EXPERIMENTAL
Intervention: Reiki intervention applied for three sessions of 35-40 minutes on postpartum 1st, 2nd, and 7th days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no Reiki intervention)
Number of subjects: 86
Study: 39098048

Group type: EXPERIMENTAL
Intervention: Dehydrated human amniotic/chorionic membrane (dHACM) treatment following excisional debridement
Number of subjects: 4
Study: 39098315

Group type: EXPERIMENTAL
Intervention: Females with heterozygous familial hypercholesterolaemia
Number of subjects: 3506

Group type: EXPERIMENTAL
Intervention: Males with heterozygous familial hypercholesterolaemia
Number of subjects: 3506

Group type: COMPARATOR
Intervention: Males compared to females
Number of subjects: 3506
Study: 39098321

Group type: EXPERIMENTAL
Intervention: 200 mg fosravuconazole
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 300 mg fosravuconazole
Number of subjects: 104

Group type: COMPARATOR
Intervention: Itraconazole (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both doses of fosravuconazole
Number of subjects: 104
Study: 39098325

Group type: EXPERIMENTAL
Intervention: Usual care plus ≤6 monthly incentives (22,500 Tanzanian Shillings, about US$10 each), conditional on visit attendance.
Number of subjects: 1990

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1990
Study: 39098432

Group type: EXPERIMENTAL
Intervention: Preoperative single-dose partial breast irradiation (PBI) followed by breast-conserving surgery (BCS)
Number of subjects: 36
Study: 39098454

Group type: EXPERIMENTAL
Intervention: High pre-treatment levels of IL-6 (quartile 4 versus 1)
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Global CRF of clinical importance (EORTC QLQ-C30 ≥40/100)
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Pre-treatment inflammatory markers
Number of subjects: 1208
Study: 39098658

Group type: EXPERIMENTAL
Intervention: Statin treatment in HR patients
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Statin treatment in VHR patients
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Secondary prevention in VHR patients
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Chronic renal failure in VHR patients
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Age, BMI, and HbA1c in HR patients
Number of subjects: 441
Study: 39098761

Group type: EXPERIMENTAL
Intervention: Non-racemic amisulpride (SEP-4199) in a phase 2 placebo-controlled trial
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2026
Study: 39099085

Group type: EXPERIMENTAL
Intervention: FLU-aQIV and RSVPreF3 OA co-administration (Co-Ad)
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Sequential administration of FLU-aQIV and RSVPreF3 OA (Control)
Number of subjects: 1045
Study: 39099093

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1152
Study: 39099801

Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 39100428

Group type: EXPERIMENTAL
Intervention: Video education plus behavior contract (n = 91)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard education (n = 82)
Number of subjects: 173
Study: 39100527

Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: High number of sexual partners
Number of subjects: 417
Study: 39100571

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day) for 8 weeks
Number of subjects: 67
Study: 39101114

Group type: EXPERIMENTAL
Intervention: DCB-based PCI
Number of subjects: 360

Group type: COMPARATOR
Intervention: DES-only PCI
Number of subjects: 360
Study: 39101128

Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: rFIXFc
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: rFVIIIFc/rFIXFc
Number of subjects: 197
Study: 39101201

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 39101209

Group type: EXPERIMENTAL
Intervention: Postoperative complications (including delayed gastric emptying)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Clavien-Dindo grade 3b to 4 complications
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Grade 3b and 4 complications in pancreatic cancer patients
Number of subjects: 528
Study: 39101472

Group type: EXPERIMENTAL
Intervention: Inclisiran as adjunct to high-intensity statin therapy with or without ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ezetimibe as adjunct to high-intensity statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evolocumab as adjunct to high-intensity statin therapy and ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo as adjunct to high-intensity statin therapy with or without ezetimibe
Number of subjects: 0
Study: 39101506

Group type: COMPARATOR
Intervention: Behavioural support or system-change interventions
Number of subjects: 9959

Group type: COMPARATOR
Intervention: Warm handoff system-change intervention
Number of subjects: 9959

Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 9959

Group type: COMPARATOR
Intervention: Behavioural support plus nicotine replacement therapy (NRT)
Number of subjects: 9959

Group type: COMPARATOR
Intervention: Behavioural support plus NRT
Number of subjects: 9959
Study: 39101607

Group type: EXPERIMENTAL
Intervention: SPT (Surgery with Postoperative Physical Therapy)
Number of subjects: 97

Group type: COMPARATOR
Intervention: CO (Crossover from PTA to SPT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: PTA (Physical Therapy Alone)
Number of subjects: 97
Study: 39101654

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (NAIT)
Number of subjects: 47
Study: 39101698

Group type: EXPERIMENTAL
Intervention: Secukinumab every 2 weeks (SECQ2W)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Secukinumab every 4 weeks (SECQ4W)
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study: 39101738

Group type: EXPERIMENTAL
Intervention: Knee arthroscopy in addition to exercise therapy (n=150)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Exercise therapy alone (n=150)
Number of subjects: 150
Study: 39101915

Group type: EXPERIMENTAL
Intervention: Food Addiction Symptom Inventory (FASI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yale Food Addiction Scale (YFAS)
Number of subjects: 0
Study: 39102049

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 2400 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 39102111

Group type: EXPERIMENTAL
Intervention: High protein and low glycemic load diet (1.3-1.4 g/kg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional diet (0.8-1.0 g/kg/day of protein)
Number of subjects: 120
Study: 39102242

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm using full FAF images as benchmark
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ablation experiments with No Lesion, No Rim, and No Background datasets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convex Hull dataset to evaluate lesion size
Number of subjects: 0
Study: 39102249

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (physiotherapy plus cognitive behavioral therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control intervention (psychological support intervention)
Number of subjects: 40
Study: 39102302

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39102464

Group type: EXPERIMENTAL
Intervention: Young adults exposed to 40°C, 9% relative humidity
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Older adults exposed to a range of conditions (31°C-40°C, 9-45% RH)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Young adults in 40°C, 9% RH
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Older adults in 40°C, 9% RH
Number of subjects: 83
Study: 39102622

Group type: EXPERIMENTAL
Intervention: MDT plus systemic therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic therapy (control)
Number of subjects: 40
Study: 39102624

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 906

Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year
Number of subjects: 906
Study: 39102712

Group type: EXPERIMENTAL
Intervention: Mind-body medicine stress management and lifestyle modification (MBM) program, duration 9 months, guided intervention group (IG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-guided waitlist control group (CG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mind-body medicine program (both guided and self-directed)
Number of subjects: 0
Study: 39102756

Group type: EXPERIMENTAL
Intervention: Camrelizumab, apatinib, and capecitabine combination therapy
Number of subjects: 28
Study: 39102832

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 551
Study: 39103234

Group type: EXPERIMENTAL
Intervention: Combination of monofocal and EDOF IOL implantation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Bilateral monofocal IOL implantation
Number of subjects: 88
Study: 39103472

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measurement
Number of subjects: 235
Study: 39103508

Group type: EXPERIMENTAL
Intervention: Tempus xT CDx assay for detecting HLA LOH
Number of subjects: 10982

Group type: EXPERIMENTAL
Intervention: HLA-A LOH
Number of subjects: 10982

Group type: EXPERIMENTAL
Intervention: Tempus AWARE program
Number of subjects: 10982
Study: 39103546

Group type: EXPERIMENTAL
Intervention: SFC (30% sunflower seed flour)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: WWC (30% whole wheat flour)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CC (control cracker with conventional flour)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose reference drink
Number of subjects: 11
Study: 39103661

Group type: EXPERIMENTAL
Intervention: Nebulised modified cyanoacrylate (1 mL) for anastomotic reinforcement
Number of subjects: 152

Group type: COMPARATOR
Intervention: No reinforcement (control group)
Number of subjects: 152
Study: 39103782

Group type: EXPERIMENTAL
Intervention: Combined bilateral parasternal block (PSB) and serratus anterior plane block (SAPB)
Number of subjects: 20